Kauffman had been with the company since 2005 and was named vice-chairman in 2008. IsoRay is looking to fill the hole he left behind, but there are no immediate nominations or arrangements, according to an IsoRay regulatory filing.
MASSDEVICE ON CALL — Rep. Erik Paulsen’s long-running effort to repeal the medical device excise tax is nearing a climax in the House, the Congressman said during a recent episode of his regular "Correspondence Corner" videos.
Before answering questions sent by his constituents, Paulsen gave a shout out to Minnesota medical device makers and said he expects his tax repeal bill to get a House vote this week.
Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
The U.S. Supreme Court heard oral arguments this week in a case that could have wide-reaching implications for health care: Whether medical patents should be allowed.
At issue is the specter of doctors being sued for patent infringement based on treatment decisions derived from the scientific research underpinning the patent.
Medtronic Inc. (NYSE:MDT) won FDA clearance for its next generation iPro2 Professional continuous glucose monitor.
The iPro2 Professional is a clinician-owned device that collects glucose data from a sensor inserted into a patient’s skin.
The device tracks the patient’s glucose levels for 3 days, collecting data as many as 288 times each day. The information may provide insight into how diet, medication and daily activities affect a patient’s glucose levels.
Microcatheter maker iScience Interventional announced an investment by med-tech goliath Medtronic Inc. (NYSE:MDT) to support the commercialization of its drug delivery technologies.
The Menlo Park, Calif.-based company’s microcatheter is used during the surgical treatment of glaucoma to deliver drugs to the eye.
Biomet Inc.’s first-quarter losses widened significantly despite nearly 4 percent top-line growth during the three months ended August 31.
The privately owned orthopedics giant posted losses of $39 million on sales of $665 million during the quarter, up 120.2 percent and 3.7 percent, respectively, over Q1 2011.